Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.

Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.

Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.

Abstract: The present invention relates to the field of veterinary vaccines, in particular to porcine vaccines against PCV2 and associated diseases. Specifically the invention relates to the finding that a mutation is required in PCV2b ORF2 protein, to prevent its nuclear accumulation upon expression in insect cells; the mutation introduces a Proline at amino acid position 131. This allows efficient expression in insect cells, easy harvesting, and generates large amounts of virus-like particles. The VLPs are highly effective in vaccines for porcines for reduction of infection by PCV2 or of associated signs of disease.

Abstract: The present invention relates to the field of veterinary vaccines, in particular to porcine vaccines against PCV2 and associated diseases. Specifically the invention relates to the finding that a mutation is required in PCV2b ORF2 protein, to prevent its nuclear accumulation upon expression in insect cells; the mutation introduces a Proline at amino acid position 131. This allows efficient expression in insect cells, easy harvesting, and generates large amounts of virus-like particles. The VLPs are highly effective in vaccines for porcines for reduction of infection by PCV2 or of associated signs of disease.

Abstract: The present invention regards a new and Improved HVT-vectored ND-IBD vaccine, comprising a recombinant HVT comprising the VP2 gene from IBDV and the F gene from NDV to a target animal. The recombinant HVT can be used in a vaccine for poultry, which displayed good viral vector replication, effective expression of the NDV F- and IBDV VP2 genes, improved immunoprotection against ND and IBD, and improved genetic stability over prior art constructs.

Abstract: The present invention regards a new and Improved HVT-vectored ND-IBD vaccine, comprising a recombinant HVT comprising the VP2 gene from IBDV and the F gene from NDV to a target animal. The recombinant HVT can be used in a vaccine for poultry, which displayed good viral vector replication, effective expression of the NDV F—and IBDV VP2 genes, improved immunoprotection against ND and IBD, and improved genetic stability over prior art constructs.

Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.

Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.

Abstract: The present invention relates to the field of veterinary vaccines, in particular to that of vector vaccines for poultry based on recombinant nonpathogenic Marek's disease virus (npMDV). The recombinant npMDV of the invention expresses stably and effectively two heterologous genes each originating from a different micro-organism: the fusion protein gene from Newcastle disease virus, and the viral protein 2 gene from infectious bursal disease virus. A vaccine based on this recombinant npMDV can be used to induce in poultry a protective immune response not only against Marek's disease, but also against Newcastle disease and Infectious bursal disease. The invention also relates to methods and uses involving the recombinant npMDV, expression cassette, infected host cells, and vaccines.

Abstract: The present application applies to the field of veterinary vaccines, in particular of vaccines for poultry against avian influenza. The vaccine is based on a recombinant viral vector expressing the haemagglutinin protein of an influenza virus, wherein the vector is herpes virus of turkeys (HVT) and the haemagglutinin gene is driven by a glycoprotein B gene promoter from a mammalian herpesvirus. A vaccine comprising this HVT+HA vector can be used to induce a protective immune response against avian influenza in poultry, and to reduce the spread of AIV. The invention also relates to methods, uses, and vaccines involving the HVT+HA vector.

Abstract: The present invention relates to recombinant C. difficile toxin A (TcdA) and toxin B (TcdB) and binary toxin A (CDTa) proteins comprising specifically defined mutations relative to the native toxin sequence that substantially reduce or eliminate toxicity. The invention also relates to vaccines and immunogenic compositions comprising these recombinant toxins, as well as combinations of these toxins with binary toxin B (CDTb), which are capable of providing protection against C. difficile infection and/or the effects thereof. The invention also relates to methods of inducing an immune response to C. difficile comprising administering the vaccines and immunogenic compositions described herein to a patient. The invention also encompasses methods of expressing recombinant C. difficile toxin A and toxin B and CDTa mutants and CDTb in recombinant expression systems.

Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.

Abstract: The present invention relates to the field of veterinary vaccines, in particular to that of vector vaccines for poultry based on recombinant nonpathogenic Marek's disease virus (npMDV). The recombinant npMDV of the invention expresses stably and effectively two heterologous genes each originating from a different micro-organism: the fusion protein gene from Newcastle disease virus, and the viral protein 2 gene from infectious bursal disease virus. A vaccine based on this recombinant npMDV can be used to induce in poultry a protective immune response not only against Marek's disease, but also against Newcastle disease and Infectious bursal disease. The invention also relates to methods and uses involving the recombinant npMDV, expression cassette, infected host cells, and vaccines.

Abstract: The present application applies to the field of veterinary vaccines, in particular of vaccines for poultry against avian influenza. The vaccine is based on a recombinant viral vector expressing the haemagglutinin protein of an influenza virus, wherein the vector is herpes virus of turkeys (HVT) and the haemagglutinin gene is driven by a glycoprotein B gene promoter from a mammalian herpesvirus. A vaccine comprising this HVT+HA vector can be used to induce a protective immune response against avian influenza in poultry, and to reduce the spread of AIV. The invention also relates to methods, uses, and vaccines involving the HVT+HA vector.

Abstract: The present invention relates to novel Equine herpesvirus (EHV) mutants comprising one or more deletions, substitutions, or insertions in the endogenous promoter region of an essential viral gene, preferably the immediate early gene of EHV. The EHV mutants are stable and have reduced virulence, which makes them very suitable for use in a live vaccine. The invention furthermore relates to live vaccines comprising said EHV mutants, to DNA sequences and vectors harbouring a mutated EHV sequence, to host cells transfected with said DNA or vectors. The invention also relates to a method of attenuating EHV in general, and EHV-1 in particular.

Abstract: The present invention is concerned with a Feline Herpesvirus (FHV) mutant comprising a heterologous gene or foreign DNA inserted into a section of the FHV genome. The invention also relates to a vector vaccine comprising a recombinant FHV mutant which expresses a heterologous polypeptide derived from a feline pathogen and a pharmaceutically acceptable carrier and induces an immune response in an inoculated host against both FHV and the feline pathogen.

Abstract: The invention is related to a nucleic acid sequence encoding a MD06 Marek's Disease Virus protein. Such a protein can be used for the immunization of poultry against MDV infection or disease. The nucleic acid sequence encoding the MD06 MDV protein can be applied for the preparation of the protein by means of genetic engineering techniques or can be applied for the preparation of vector vaccines.

Abstract: The present invention is concerned with a Feline herpesvirus (FHV) mutant comprising a heterologous gene introduced into an insertion-region of the FHV genome.The invention also relates to a vector vaccine comprising such an FHV mutant which expresses a heterologous polypeptide derived from a feline pathogen and induces an adequate immune response in an inoculated host against both FHV and the feline pathogen.

Abstract: The invention is related to a nucleic acid sequence encoding a MD06 Marek's Disease Virus protein. Such a protein can be used for the immunization of poultry against MDV infection or disease. The nucleic acid sequence encoding the MD06 MDV protein can be applied for the preparation of the protein by means of genetic engineering techniques or can be applied for the preparation of vector vaccines.